HANGZHOU TIGERMED CONSULTING (300347) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was RMB 1.56 billion, down 5.79% year-over-year; net profit attributable to shareholders was RMB 165 million, down 29.61% year-over-year.

• New contract value exceeded RMB 2 billion in Q1, up 20% year-over-year, with strong recovery in domestic client orders.

• Significant investment in digitalization and intelligent technology development continued in line with strategic planning.

Financial highlights

• Operating cash flow increased 37.26% year-over-year to RMB 198 million.

• Total assets at quarter-end were RMB 28.73 billion, up 0.20% from year-end 2024.

• Net profit excluding non-recurring items was RMB 102 million, down 66.23% year-over-year.

• Basic and diluted EPS were both RMB 0.19, down 29.63% year-over-year.

Key financial ratios and metrics

• Weighted average ROE was 0.80%, down from 1.12% in Q1 2024.

• Owner's equity attributable to shareholders was RMB 20.53 billion, down 0.68% from year-end.